US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

49.09

-1.4300-2.83%

Post-market: 49.200.1100+0.22%19:59 EDT

Volume:592.57K

Turnover:29.71M

Market Cap:3.50B

PE:-15.77

High:51.11

Open:50.70

Low:49.01

Close:50.52

52wk High:94.90

52wk Low:18.26

Shares:71.31M

Float Shares:54.64M

Volume Ratio:0.80

T/O Rate:1.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1128

EPS(LYR):-2.3852

ROE:-20.21%

ROA:-14.95%

PB:2.58

PE(LYR):-20.58

Loading ...

Overview Company News Filings

Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed?

Simply Wall St.

Structure Therapeutics presents Phase 2b ACCESS obesity trial data for aleniglipron at ADA 2026

Structure Therapeutics Initiated at Buy by Canaccord Genuity

Structure Therapeutics initiated with a Buy at Canaccord

Structure Therapeutics announces annual general meeting webcast for shareholders

Structure Therapeutics COO, GC Matthew Lang files initial beneficial ownership statement

Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial?

Simply Wall St.

Press Release: AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Is Structure Therapeutics (GPCR) Building a Legal-Led Edge in Its Obesity and Metabolic Pipeline Strategy?

Simply Wall St.

BRIEF-Structure Therapeutics Appoints Matthew Lang, J.D. As Chief Operating Officer And General Counsel

Structure Therapeutics names Matthew Lang COO, general counsel

Structure Therapeutics Appoints Matthew Lang, J.d. as Chief Operating Officer and General Counsel

THOMSON REUTERS

Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target

Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy?

Simply Wall St.

BUZZ-Lilly obesity pill approval creates an opening for Structure's drug, says H.C. Wainwright

What's Going On With Structure Therapeutics Stock On Wednesday?

Lilly’s Centessa Deal Highlights Nxera Pharma’s GPCR Platform Strength

Structure Therapeutics (GPCR) Is Down 5.5% After Strong Oral GLP-1 Phase 2 Data - What's Changed

Simply Wall St.

Structure Therapeutics Obesity Trial Success Puts Valuation Gap In Focus

Simply Wall St.

LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/GPCR/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":49.09,"timestamp":1787342400000,"preClose":50.52,"halted":0,"volume":592574,"hourTrading":{"tag":"盘后","latestPrice":49.2,"preClose":49.09,"latestTime":"19:59 EDT","volume":44750,"amount":2196926.26,"timestamp":1787356775142,"change":0.11,"changeRate":0.002241,"amplitude":0.010389},"delay":0,"changeRate":-0.028305621536025328,"floatShares":54641899,"shares":71309857,"eps":-3.1128,"marketStatus":"Market Closed","change":-1.43,"latestTime":"08-21 16:00:00 EDT","open":50.7,"high":51.11,"low":49.01,"amount":29714636.859202,"amplitude":0.041568,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.1128,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":50.52,"preHourTrading":{"tag":"盘前","latestPrice":51.2,"preClose":50.52,"latestTime":"09:15 EDT","volume":721,"amount":36627.699087,"timestamp":1787318123448,"change":0.68,"changeRate":0.01346,"amplitude":0.054236},"postHourTrading":{"tag":"盘后","latestPrice":49.2,"preClose":49.09,"latestTime":"19:59 EDT","volume":44750,"amount":2196926.26,"timestamp":1787356775142,"change":0.11,"changeRate":0.002241,"amplitude":0.010389},"volumeRatio":0.8033914747715426,"impliedVol":0.7978,"impliedVolPercentile":0.5777},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":54641899,"roa":"-14.95%","roe":"-20.21%","lyrEps":-2.385222,"volumeRatio":0.8033914747715426,"shares":71309857,"dividePrice":0,"high":51.11,"amplitude":0.041568,"preClose":50.52,"low":49.01,"week52Low":18.264,"pbRate":"2.58","week52High":94.9,"institutionHeld":0,"latestPrice":49.09,"eps":-3.1128,"divideRate":0,"volume":592574,"delay":0,"ttmEps":-3.1128,"open":50.7,"prevYearClose":69.55,"prevWeekClose":54.51,"prevMonthClose":48.04,"prevQuarterClose":53.67,"fiveDayClose":54.51,"twentyDayClose":49.12,"sixtyDayClose":39.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GPCR","fiscalQuarterEnding":"2026/06","expectedEps":-0.39,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2026-05-07","symbol":"GPCR","fiscalQuarterEnding":"2026/03","expectedEps":-0.39,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.35},{"market":"US","date":"2026-02-26","symbol":"GPCR","fiscalQuarterEnding":"2025/12","expectedEps":-0.35,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-11-06","symbol":"GPCR","fiscalQuarterEnding":"2025/09","expectedEps":-0.36,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.37},{"market":"US","date":"2025-08-06","symbol":"GPCR","fiscalQuarterEnding":"2025/06","expectedEps":-0.28,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.36}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3529,"buy":0.5882,"hold":0.0588,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5882,"analysts":17,"updateTime":1777348800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2026-08-21","current":-15.770368,"percent":0.668591,"low":-50.180001,"twenty":-24.436431,"median":-19.854838,"eighty":-10.567565,"high":-5.211405,"avg":-19.432697,"sd":8.246779,"marketCap":3602573975},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-05-02","current":-12.790591,"twenty":-25.171712,"median":-20.933479,"eighty":-16.305436,"marketCap":1567180008},{"date":"2025-05-09","current":-12.551909,"twenty":-25.070517,"median":-20.891345,"eighty":-16.181125,"marketCap":1537935156},{"date":"2025-05-16","current":-9.774326,"twenty":-25.068859,"median":-20.829252,"eighty":-16.056814,"marketCap":1400885752},{"date":"2025-05-23","current":-9.895696,"twenty":-25.0453,"median":-20.693431,"eighty":-15.839386,"marketCap":1418280862},{"date":"2025-05-30","current":-9.000467,"twenty":-25.01052,"median":-20.672234,"eighty":-15.745511,"marketCap":1289973912},{"date":"2025-06-06","current":-8.619091,"twenty":-25.001825,"median":-20.550917,"eighty":-15.544032,"marketCap":1235314001},{"date":"2025-06-13","current":-8.920177,"twenty":-24.996225,"median":-20.487391,"eighty":-15.387426,"marketCap":1278466562},{"date":"2025-06-20","current":-8.679308,"twenty":-24.952868,"median":-20.449033,"eighty":-14.973238,"marketCap":1243944513},{"date":"2025-06-27","current":-8.462526,"twenty":-24.918331,"median":-20.434088,"eighty":-14.66039,"marketCap":1212874668},{"date":"2025-07-03","current":-8.175491,"twenty":-24.875783,"median":-20.408464,"eighty":-14.607558,"marketCap":1171735893},{"date":"2025-07-11","current":-7.587369,"twenty":-24.818526,"median":-20.385744,"eighty":-14.451133,"marketCap":1087444556},{"date":"2025-07-18","current":-7.840282,"twenty":-24.807686,"median":-20.281918,"eighty":-14.123781,"marketCap":1123692707},{"date":"2025-07-25","current":-7.334457,"twenty":-24.781668,"median":-20.180483,"eighty":-13.987039,"marketCap":1051196404},{"date":"2025-08-01","current":-7.145777,"twenty":-24.722332,"median":-20.085721,"eighty":-13.108576,"marketCap":1024154132},{"date":"2025-08-08","current":-5.211405,"twenty":-24.651853,"median":-19.971704,"eighty":-12.812535,"marketCap":932580977},{"date":"2025-08-15","current":-5.964179,"twenty":-24.61951,"median":-19.937893,"eighty":-12.626872,"marketCap":1067289809},{"date":"2025-08-22","current":-6.234546,"twenty":-24.540145,"median":-19.829477,"eighty":-12.490132,"marketCap":1115672078},{"date":"2025-08-29","current":-6.160517,"twenty":-24.4698,"median":-19.66456,"eighty":-12.119485,"marketCap":1102424552},{"date":"2025-09-05","current":-6.360074,"twenty":-24.389808,"median":-19.576169,"eighty":-11.77845,"marketCap":1138135274},{"date":"2025-09-12","current":-6.720564,"twenty":-24.139365,"median":-19.456275,"eighty":-11.057099,"marketCap":1202644966},{"date":"2025-09-19","current":-7.47695,"twenty":-24.11098,"median":-19.134734,"eighty":-10.896967,"marketCap":1338000122},{"date":"2025-09-26","current":-8.043434,"twenty":-24.072254,"median":-19.014985,"eighty":-10.567565,"marketCap":1439372495},{"date":"2025-10-03","current":-8.568076,"twenty":-24.020356,"median":-18.941828,"eighty":-10.325716,"marketCap":1533257136},{"date":"2025-10-10","current":-9.833009,"twenty":-23.986828,"median":-18.81071,"eighty":-10.186609,"marketCap":1759617036},{"date":"2025-10-17","current":-8.87063,"twenty":-23.947347,"median":-18.74276,"eighty":-9.917033,"marketCap":1587399198},{"date":"2025-10-24","current":-8.548764,"twenty":-23.914099,"median":-18.661907,"eighty":-9.852324,"marketCap":1529801259},{"date":"2025-10-31","current":-10.370526,"twenty":-23.886602,"median":-18.351918,"eighty":-9.836476,"marketCap":1855805594},{"date":"2025-11-07","current":-10.772858,"twenty":-23.868757,"median":-18.327399,"eighty":-9.850579,"marketCap":1927803018},{"date":"2025-11-14","current":-10.08006,"twenty":-23.852048,"median":-18.288418,"eighty":-9.817863,"marketCap":2123717400},{"date":"2025-11-21","current":-9.889979,"twenty":-23.841601,"median":-18.256152,"eighty":-9.836476,"marketCap":2083670157},{"date":"2025-11-28","current":-10.313341,"twenty":-23.799814,"median":-18.097181,"eighty":-9.841018,"marketCap":2172866288},{"date":"2025-12-05","current":-9.460856,"twenty":-23.776121,"median":-18.070517,"eighty":-9.814076,"marketCap":1993260474},{"date":"2025-12-12","current":-19.422835,"twenty":-23.650834,"median":-18.082412,"eighty":-9.833009,"marketCap":4092100041},{"date":"2025-12-19","current":-17.985707,"twenty":-23.62393,"median":-18.070517,"eighty":-9.841018,"marketCap":3789318618},{"date":"2025-12-26","current":-22.869735,"twenty":-23.621272,"median":-18.100056,"eighty":-9.848479,"marketCap":4818310220},{"date":"2026-01-02","current":-22.823793,"twenty":-23.615623,"median":-18.255492,"eighty":-9.851048,"marketCap":4808630734},{"date":"2026-01-09","current":-21.980412,"twenty":-23.576442,"median":-18.281194,"eighty":-9.851517,"marketCap":4630943013},{"date":"2026-01-16","current":-27.900487,"twenty":-23.621936,"median":-18.326514,"eighty":-9.853937,"marketCap":5878214018},{"date":"2026-01-23","current":-30.148409,"twenty":-23.790337,"median":-18.349084,"eighty":-9.86147,"marketCap":6351817477},{"date":"2026-01-30","current":-28.599475,"twenty":-23.883185,"median":-18.63625,"eighty":-9.874048,"marketCap":6025480495},{"date":"2026-02-06","current":-24.024872,"twenty":-24.012922,"median":-18.680713,"eighty":-9.881446,"marketCap":5061680173},{"date":"2026-02-13","current":-23.64092,"twenty":-24.104146,"median":-18.735704,"eighty":-9.886523,"marketCap":4980787319},{"date":"2026-02-20","current":-22.141212,"twenty":-24.072254,"median":-18.787312,"eighty":-9.891122,"marketCap":4664821216},{"date":"2026-02-27","current":-21.248606,"twenty":-24.026331,"median":-18.905431,"eighty":-9.903769,"marketCap":4476762617},{"date":"2026-03-06","current":-29.951815,"twenty":-24.389808,"median":-18.958825,"eighty":-9.939515,"marketCap":4229256176},{"date":"2026-03-13","current":-27.383083,"twenty":-24.63457,"median":-19.091174,"eighty":-9.953915,"marketCap":3866546098},{"date":"2026-03-20","current":-25.316057,"twenty":-24.813106,"median":-19.247915,"eighty":-9.965451,"marketCap":3574677833},{"date":"2026-03-27","current":-23.178791,"twenty":-24.786548,"median":-19.412443,"eighty":-10.00684,"marketCap":3272891714},{"date":"2026-04-02","current":-25.170562,"twenty":-24.791427,"median":-19.500107,"eighty":-10.024679,"marketCap":3554133708},{"date":"2026-04-10","current":-27.664038,"twenty":-24.924896,"median":-19.588971,"eighty":-10.070397,"marketCap":3906217513},{"date":"2026-04-17","current":-26.841241,"twenty":-25.001825,"median":-19.762743,"eighty":-10.08006,"marketCap":3790036942},{"date":"2026-04-24","current":-23.59019,"twenty":-25.001825,"median":-19.852578,"eighty":-10.16646,"marketCap":3330982000},{"date":"2026-05-01","current":-20.863024,"twenty":-25.001825,"median":-19.937893,"eighty":-10.183801,"marketCap":2945900742},{"date":"2026-05-08","current":-19.705365,"twenty":-24.994825,"median":-19.961493,"eighty":-10.197841,"marketCap":2782437010},{"date":"2026-05-15","current":-16.62279,"twenty":-24.933886,"median":-19.910742,"eighty":-10.230435,"marketCap":2831476129},{"date":"2026-05-22","current":-16.184689,"twenty":-24.924896,"median":-19.829477,"eighty":-10.235281,"marketCap":2756851382},{"date":"2026-05-29","current":-20.218762,"twenty":-24.916142,"median":-19.78569,"eighty":-10.28472,"marketCap":2854929621},{"date":"2026-06-05","current":-19.660066,"twenty":-24.837612,"median":-19.705365,"eighty":-10.310089,"marketCap":2776040603},{"date":"2026-06-12","current":-21.794185,"twenty":-24.818526,"median":-19.734054,"eighty":-10.313341,"marketCap":3077382440},{"date":"2026-06-18","current":-18.776621,"twenty":-24.802267,"median":-19.684963,"eighty":-10.332349,"marketCap":3198353220},{"date":"2026-06-26","current":-20.13271,"twenty":-24.776789,"median":-19.66456,"eighty":-10.358393,"marketCap":3429345397},{"date":"2026-07-02","current":-21.747499,"twenty":-24.722332,"median":-19.762743,"eighty":-10.368595,"marketCap":3704403773},{"date":"2026-07-10","current":-23.007619,"twenty":-24.651853,"median":-19.829477,"eighty":-10.39842,"marketCap":3919048812},{"date":"2026-07-17","current":-19.206397,"twenty":-24.633491,"median":-19.854838,"eighty":-10.468301,"marketCap":3271559971},{"date":"2026-07-24","current":-21.196718,"twenty":-24.602614,"median":-19.924318,"eighty":-10.512193,"marketCap":3610585412},{"date":"2026-07-31","current":-20.641765,"twenty":-24.584569,"median":-19.948142,"eighty":-10.52082,"marketCap":3516056306},{"date":"2026-08-07","current":-21.956128,"twenty":-24.559431,"median":-19.978813,"eighty":-10.545017,"marketCap":3739941031},{"date":"2026-08-14","current":-18.156488,"twenty":-24.476043,"median":-19.948142,"eighty":-10.550775,"marketCap":3900649177},{"date":"2026-08-21","current":-16.769027,"twenty":-24.436431,"median":-19.854838,"eighty":-10.567565,"marketCap":3602573975}],"updateTime":1787427786337},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2632002966","title":"Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632002966","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632002966?lang=en_us&edition=fundamental","pubTime":"2026-05-03 22:18","pubTimestamp":1777817901,"startTime":"0","endTime":"0","summary":"Structure Therapeutics previously reported encouraging Phase 2 ACCESS II trial results for its oral GLP-1 receptor agonist aleniglipron, showing up to 16.3% weight reduction in adults with obesity and outlining plans to meet the FDA in Q2 2026 ahead of Phase 3 trials in the second half of 2026.\nThe data position aleniglipron as one of the most effective oral GLP-1 candidates so far, highlighting a potentially meaningful differentiation versus other pill-based obesity treatments.\nNext, we...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/structure-therapeutics-gpcr-is-down-72-after-strong-phase-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/structure-therapeutics-gpcr-is-down-72-after-strong-phase-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4599","GLP","BK4144","BK4590","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630312078","title":"Structure Therapeutics presents Phase 2b ACCESS obesity trial data for aleniglipron at ADA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630312078","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630312078?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:07","pubTimestamp":1777320443,"startTime":"0","endTime":"0","summary":"Structure Therapeutics scheduled new Phase 2b ACCESS trial results for oral obesity drug candidate aleniglipron for presentation at American Diabetes Association 86th Scientific Sessions on June 5, 2026.Planned presentation highlights meaningful weight reduction in people with obesity or overweight, supporting continued clinical development of an oral small-molecule GLP-1 option.Separate Phase 2 ACCESS II data on safety, tolerability, and efficacy at higher doses will be presented on June 8, 2026.Late-breaking posters on June 7, 2026 will outline work to improve gastrointestinal tolerability with a lower starting dose, alongside preclinical combination findings pairing aleniglipron with amylin candidate ACCG-2671 that showed additional weight loss versus single-agent treatment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL7jfGwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","BK4599","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014039.USD","BK4007","BK4588","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","LU2210150020.SGD","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","GPCR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630394424","title":"Structure Therapeutics Initiated at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2630394424","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630394424?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:08","pubTimestamp":1777295280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GPCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 09:08 ET (13:08 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630500362","title":"Structure Therapeutics initiated with a Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2630500362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630500362?lang=en_us&edition=fundamental","pubTime":"2026-04-27 18:00","pubTimestamp":1777284027,"startTime":"0","endTime":"0","summary":"Canaccord initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $101 price target Published first on TheFly – the ultimate sour...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-initiated-with-a-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-initiated-with-a-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4539","GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629786534","title":"Structure Therapeutics announces annual general meeting webcast for shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2629786534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629786534?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:39","pubTimestamp":1776976763,"startTime":"0","endTime":"0","summary":"Structure Therapeutics scheduled virtual annual general meeting for June 17, 2026.Shareholders will vote on election of three Class III director nominees to serve until 2029 annual meeting.Meeting agenda also includes advisory vote on compensation for named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLb0MW5k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629868025","title":"Structure Therapeutics COO, GC Matthew Lang files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629868025","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629868025?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:20","pubTimestamp":1776975629,"startTime":"0","endTime":"0","summary":"Structure Therapeutics filed an initial Form 3 for Matthew Lang, COO and general counsel, dated April 15.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLbHhlF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629054139","title":"Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629054139","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629054139?lang=en_us&edition=fundamental","pubTime":"2026-04-22 01:09","pubTimestamp":1776791388,"startTime":"0","endTime":"0","summary":"Septerna, Inc. recently began dosing healthy volunteers in a randomized, placebo-controlled Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, using single-ascending and multiple-ascending dose designs to assess safety, tolerability, pharmacokinetics and pharmacodynamics.\nThis first-in-human study, which could enroll up to 150 participants and tracks biomarkers such as endogenous PTH and serum calcium, marks a key progression of Septerna’s GPCR-targeted pipeline into...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/is-septerna-sepn-quietly-redefining-its-gpcr-strategy-with-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/is-septerna-sepn-quietly-redefining-its-gpcr-strategy-with-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SEPN","BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628725402","title":"Press Release: AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2628725402","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628725402?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:16","pubTimestamp":1776690960,"startTime":"0","endTime":"0","summary":"AbCellera  today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 earnings call on Monday, May 11, 2026.ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor  for the non-hormonal treatment of moderate-to-severe vasomotor symptoms  associated with menopause. It is currently being evaluated in a Phase 1/2 study, and the results of the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-to-severe VMS are anticipated in Q3 2026.As previously announced, AbCellera will host its first quarter 2026 earnings call on Monday, May 11, 2026 at 2:00 p.m. PT . A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be avai","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABCL","BK4007","GPCR","BK4599","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628761856","title":"Is Structure Therapeutics (GPCR) Building a Legal-Led Edge in Its Obesity and Metabolic Pipeline Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2628761856","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628761856?lang=en_us&edition=fundamental","pubTime":"2026-04-19 15:06","pubTimestamp":1776582367,"startTime":"0","endTime":"0","summary":"Earlier this month, Structure Therapeutics Inc. appointed Matthew Lang, J.D. as Chief Operating Officer and General Counsel, bringing more than fifteen years of executive leadership experience across global biopharmaceutical companies.\nHis track record guiding Metsera Inc. through an up to US$10.00 billion acquisition by Pfizer and helping lead Myovant’s Phase 3 development, approvals, commercialization, and ex-US operations highlights the breadth of expertise he now brings to Structure...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/is-structure-therapeutics-gpcr-building-a-legal-led-edge-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/is-structure-therapeutics-gpcr-building-a-legal-led-edge-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627421637","title":"BRIEF-Structure Therapeutics Appoints Matthew Lang, J.D. As Chief Operating Officer And General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2627421637","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627421637?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:09","pubTimestamp":1776197348,"startTime":"0","endTime":"0","summary":"BRIEF-Structure Therapeutics Appoints Matthew Lang, J.D. As Chief Operating Officer And General CounselApril 14 (Reuters) - Structure Therapeutics Inc GPCR.O:STRUCTURE THERAPEUTICS APPOINTS MATTHEW LA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUAW6ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627421596","title":"Structure Therapeutics names Matthew Lang COO, general counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2627421596","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627421596?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:05","pubTimestamp":1776197134,"startTime":"0","endTime":"0","summary":"Structure Therapeutics appointed Matthew Lang as chief operating officer, general counsel.Lang previously served as chief legal officer, secretary at Metsera, where he helped guide company through its up to USD 10 billion acquisition by Pfizer.Earlier roles included chief business, legal officer at Lyell Immunopharma.He also held multiple executive posts at Myovant Sciences, supporting Phase 3 development, approvals, commercialization for Myfembree and Orgovyx.Appointment comes as Structure prepares to move oral obesity candidate aleniglipron into Phase 3.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL9BSxtl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","BK4585","IE0002270589.USD","SG9999001176.USD","BK4539","LU2095319765.USD","SGXZ57979304.SGD","LU2210149790.SGD","LU0058720904.USD","SG9999002224.SGD","LU0234572021.USD","LU0321505439.SGD","LU1894683348.USD","IE00BKPKM429.USD","LU0170899867.USD","LU0306806265.USD","IE00B19Z3581.USD","BK4505","BK4592","LU1066051498.USD","IE00BBT3K403.USD","SG9999002232.USD","SG9999014013.SGD","SG9999013999.USD","LU0321505868.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU1894683264.USD","LU0314104364.USD","BK4534","IE00BLSP4452.SGD","LU0122379950.USD","SG9999014039.USD","BK4533","BK4588","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0225771236.USD","IE00BN0W2T93.GBP","LU0868494617.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU0456855351.SGD","BK4581","LU0225284248.USD","LU0289739699.SGD","LU0306807586.USD","SG9999001176.SGD","LU1057294990.SGD","LU1883839398.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU0985481810.HKD","BK4007","BK4139","BK4550","SG9999011175.SGD","SG9999014021.USD","BK4568","IE00BLSP4239.USD","BK4599","LU1066053197.SGD","BK4112","LU2210150020.SGD","LU1023059063.AUD","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627300421","title":"Structure Therapeutics Appoints Matthew Lang, J.d. as Chief Operating Officer and General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2627300421","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627300421?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:05","pubTimestamp":1776197100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUAW6ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627417425","title":"Septerna: Advancing GPCR Pipeline and Strategic Partnerships Support Buy Rating and $40 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2627417425","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627417425?lang=en_us&edition=fundamental","pubTime":"2026-04-14 18:35","pubTimestamp":1776162925,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Septerna, Inc. today and set a price target of $40.00. Ram Selvaraju has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/septerna-advancing-gpcr-pipeline-and-strategic-partnerships-support-buy-rating-and-40-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/septerna-advancing-gpcr-pipeline-and-strategic-partnerships-support-buy-rating-and-40-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SEPN","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627545758","title":"Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2627545758","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627545758?lang=en_us&edition=fundamental","pubTime":"2026-04-13 23:20","pubTimestamp":1776093656,"startTime":"0","endTime":"0","summary":"Septerna, Inc. recently began dosing healthy adult volunteers in a Phase 1 single- and multiple-ascending dose clinical trial of SEP-479, an oral small molecule PTH1R agonist being developed for hypoparathyroidism.\nThis marks a key progression of Septerna’s GPCR-targeted pipeline into human testing, with initial safety, PK and PD data expected in late 2026 or early 2027.\nNext, we’ll examine how initiating human dosing for SEP-479 and its focus on hypoparathyroidism could shape Septerna’s...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/is-septerna-sepn-using-its-first-pth1r-trial-to-redefine-its","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/is-septerna-sepn-using-its-first-pth1r-trial-to-redefine-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GPCR","BK4007","SEPN","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624683806","title":"BUZZ-Lilly obesity pill approval creates an opening for Structure's drug, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2624683806","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624683806?lang=en_us&edition=fundamental","pubTime":"2026-04-02 23:57","pubTimestamp":1775145445,"startTime":"0","endTime":"0","summary":"BUZZ-Lilly obesity pill approval creates an opening for Structure's drug, says H.C. Wainwright** H.C. Wainwright says Eli Lilly's FDA approval of Foundayo is a positive development for drug developer Structure Therapeutics' GPCR.O oral obesity program** Brokerage maintains a \"buy\" rating and PT of $100 on GPCR shares ** Says the approval helps define the oral obesity drug market, but Foundayo's partial GLP-1 agonist label suggests limits on weight loss, leaving room for next-generation pills such as GPCR's aleniglipron** Says aleniglipron delivered 16.3% placebo-adjusted weight loss at 44 weeks, versus 12.4% for Foundayo at 72 weeks, and had a lower discontinuation rate** Says that could position aleniglipron not just as a first-line pill, but also as a possible follow-up treatment after patients lose weight on injectables. ** \"We think aleniglipron is a more compelling step-down maintenance option than Foundayo because patients switching from Zepbound or Wegovy might experience materi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL4N40L1GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624545665","title":"What's Going On With Structure Therapeutics Stock On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624545665","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624545665?lang=en_us&edition=fundamental","pubTime":"2026-04-02 02:07","pubTimestamp":1775066820,"startTime":"0","endTime":"0","summary":"Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment, boosting sentiment.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/01/Man-Standing-On-Weight-Scale--Male-Feet-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/01/Man-Standing-On-Weight-Scale--Male-Feet-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/04/51609117/whats-going-on-with-structure-therapeutics-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/04/51609117/whats-going-on-with-structure-therapeutics-stock-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU1712237335.SGD","SG9999014898.SGD","IE00BWXC8680.SGD","SG9999015952.SGD","LU0106261372.USD","LU0787776722.HKD","IE00BKDWB100.SGD","LU1629891620.HKD","LU2023251221.USD","LU2237443465.HKD","LU1069344957.HKD","SGXZ51526630.SGD","LU2491050071.SGD","LU1974910355.USD","LU0708995401.HKD","LU0385154629.USD","IE0004445015.USD","LU0320765992.SGD","LU2471134879.HKD","IE00BJJMRX11.SGD","LU2089984988.USD","LLYZ","LU2028103732.USD","LU2491050154.USD","LU0823416689.USD","LU0323591593.USD","LU0943347566.SGD","LU0882574055.USD","LU1551013342.USD","IE00BK4W5M84.HKD","LU2361045086.USD","LU1917777945.USD","LU2106854487.HKD","IE00B1XK9C88.USD","LU1093756168.USD","LU0158827781.USD","LU0114720955.EUR","LU2471134952.CNY","LU0471298777.SGD","LU1267930730.SGD","LU1323610961.USD","LU0109391861.USD","LU1868836914.USD","LU2108987350.USD","SG9999014880.SGD","LU0353189763.USD","LU1983299246.USD","LU0823434740.USD","LU0354030438.USD","LU1623119135.USD","SG9999018857.SGD","LU0158827948.USD","BK4534","LU2602419157.SGD","LU0109394709.USD","LU0203202063.USD","LU0689472784.USD","LU1145028129.USD","LU1988902786.USD","LU2746668461.USD","LU0820562030.AUD","IE00BKPKM429.USD","LLY","LU0316494557.USD","LU2357305700.SGD","LU2360106947.USD","LLII","LU0097036916.USD","LU0882574139.USD","LU2237443382.USD","LU2552382215.SGD","LU2023250504.SGD","LU1061106388.HKD","LU0471298694.HKD","ELIS","LU0203201768.USD","LU1814569148.SGD","BK4581","IE00BFTCPJ56.SGD","SGXZ31699556.SGD","LU0061475181.USD","LU0210536198.USD","ELIL","LU2168564149.EUR","LU2462157665.USD","LU0266013472.USD","LU1127390331.HKD","LU2271345857.HKD","LU1023059063.AUD","IE00B1BXHZ80.USD","BK4539","LU0122379950.USD","LU0823434583.USD","LU2089284900.SGD","SG9999015978.USD","LU0466842654.USD","SG9999001176.SGD","LU1989771016.USD","LU2063271972.USD","LU2168563687.JPY","IE00B4R5TH58.HKD","LU1232071149.USD","LU0225283273.USD","LU2750360641.GBP","LU2750360997.AUD","LU0964807845.USD","LU2112291526.USD","IE00BN29S564.USD","LU1868837136.USD","LU2756315318.SGD","LU2168564495.EUR","IE0004445239.USD","LU2168564065.EUR","IE00BK4W5L77.USD","LU0683600562.USD","LU2265009873.SGD","LU1868836757.USD","LU0289739699.SGD","LU2552382132.HKD","LU2264538146.SGD","LU2896262040.SGD","LU1868836591.USD","LU2237443622.USD","LU2237443978.SGD","LU2471134523.USD","IE00BJT1NW94.SGD","LU2361044865.SGD","LU0354030511.USD","LU0353189680.USD","LU2236285917.USD","LU2552382058.USD","LU2471134796.USD","LU1551013425.SGD","BK4599","BK4588","SG9999015945.SGD","GPCR","IE00BFSS8Q28.SGD","LU0198837287.USD","LU0672654240.SGD","SGXZ57979304.SGD","LU1868837300.USD","BK4139","LLYX","SG9999014906.USD","LU1093756325.SGD","LU2237443549.SGD","LU2213496289.HKD","LU0006306889.USD","LU2491049909.HKD","SG9999017495.SGD","LU0417517546.SGD","LU1366192091.USD","LU0096364046.USD","LU0320765059.SGD","SG9999018865.SGD","LU2468319806.SGD","IE00B4JS1V06.HKD","BK4533","IE00B7KXQ091.USD","IE00B775H168.HKD","LU1057294990.SGD","SGXZ81514606.USD","SGXZ99366536.SGD","GB00BDT5M118.USD","LU2746668974.SGD","BK4585","LU1804176565.USD","LU0820561818.USD","LU2361044949.HKD","LU2087625088.SGD","LU2211815571.USD","SG9999001176.USD","LU1291159041.SGD","LU2237438978.USD","LU0256863811.USD","IE00BFSS7M15.SGD","LU2168564222.USD","LU1035775433.USD","LU2461242641.AUD","LU1720051108.HKD","BK4516","LU0238689110.USD","SG9999014914.USD","LU0079474960.USD","LU0432979614.USD","LU2417539215.USD","LU0456855351.SGD","LU0256863902.USD","BK4007","IE00B2B36J28.USD","LU0094547139.USD","LU1548497426.USD","IE00BJJMRZ35.SGD","LU2089283258.USD","IE00BJLML261.HKD","IE0001KFT4U8.USD","IE0009355771.USD","LU1280957306.USD","SG9999013999.USD","IE00BJJMRY28.SGD","LU0058720904.USD","LU2023250330.USD","LU0889565916.HKD","LU0820561909.HKD","IE0002141913.USD","LU1064131342.USD","LU1720051017.SGD","LU2237443895.HKD","LU2324357040.USD","IE0005OL40V9.USD","LU0786609619.USD","LU2456880835.USD","LU2756315664.SGD","SG9999015986.USD","LU0234572021.USD","LU0640476718.USD","LU2111349929.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624056196","title":"Lilly’s Centessa Deal Highlights Nxera Pharma’s GPCR Platform Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2624056196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624056196?lang=en_us&edition=fundamental","pubTime":"2026-04-01 13:04","pubTimestamp":1775019871,"startTime":"0","endTime":"0","summary":"Sosei Group ( ($JP:4565) ) has provided an announcement. Nxera Pharma said its partner Centessa Pharmaceuticals has agreed to be acquired by Eli Li...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lillys-centessa-deal-highlights-nxera-pharmas-gpcr-platform-strength?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lillys-centessa-deal-highlights-nxera-pharmas-gpcr-platform-strength?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623392563","title":"Structure Therapeutics (GPCR) Is Down 5.5% After Strong Oral GLP-1 Phase 2 Data - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2623392563","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623392563?lang=en_us&edition=fundamental","pubTime":"2026-03-30 15:10","pubTimestamp":1774854619,"startTime":"0","endTime":"0","summary":"Structure Therapeutics recently reported positive topline Phase 2 ACCESS II and related study data for aleniglipron, an oral once-daily GLP-1 receptor agonist for people living with obesity or overweight, showing clinically meaningful and statistically significant weight loss alongside a tolerability profile consistent with its drug class.\nA particularly interesting aspect is that aleniglipron’s weight loss efficacy was described as comparable to injectable GLP-1 therapies while using an...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/structure-therapeutics-gpcr-is-down-55-after-strong-oral-glp","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/structure-therapeutics-gpcr-is-down-55-after-strong-oral-glp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4599","BK4590","GLP","BK4007","BK4144","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622807870","title":"Structure Therapeutics Obesity Trial Success Puts Valuation Gap In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2622807870","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622807870?lang=en_us&edition=fundamental","pubTime":"2026-03-28 11:10","pubTimestamp":1774667443,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (NasdaqGM:GPCR) released highly positive Phase 2 topline data for its oral GLP-1 receptor agonist aleniglipron in obesity and overweight patients.\nThe new results from the ACCESS clinical program show significant weight loss, a compelling safety and tolerability profile, and low discontinuation rates.\nThe company plans to advance aleniglipron into Phase 3 trials based on these Phase 2 outcomes.\n\nStructure Therapeutics focuses on small molecule medicines, and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/structure-therapeutics-obesity-trial-success-puts-valuation","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/structure-therapeutics-obesity-trial-success-puts-valuation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4599","GPCR","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621793840","title":"LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621793840","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621793840?lang=en_us&edition=fundamental","pubTime":"2026-03-21 22:56","pubTimestamp":1774105019,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $107....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-keeps-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":95,"code":"91000000","status":"200"}]}}